Zacks Investment Research
12 Jun 2026, 10:45 UTC · 23w ago
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
Impact · against what's priced in
Adaptive Biotechnologies (ADPT) shows strong short-term momentum driven by upward earnings revisions and growth in its lead product, clonoSEQ. While the 9.7% jump reflects immediate sentiment, the underlying fundamental growth is becoming the primary catalyst for the stock.
- ADPT+0.40
No priced-in read yet





